Dimensional Fund Advisors LP Sells 6,377 Shares of Glaukos Corporation $GKOS

Dimensional Fund Advisors LP lessened its stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 3.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 199,084 shares of the medical instruments supplier's stock after selling 6,377 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.34% of Glaukos worth $21,426,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its holdings in Glaukos by 9.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier's stock valued at $158,000 after buying an additional 122 shares during the last quarter. Larson Financial Group LLC increased its position in shares of Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock valued at $39,000 after acquiring an additional 132 shares during the period. CWM LLC raised its stake in shares of Glaukos by 25.2% during the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier's stock valued at $80,000 after acquiring an additional 143 shares during the last quarter. Commonwealth Equity Services LLC raised its stake in shares of Glaukos by 1.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier's stock valued at $947,000 after acquiring an additional 144 shares during the last quarter. Finally, Evergreen Capital Management LLC boosted its holdings in shares of Glaukos by 4.3% during the fourth quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier's stock worth $401,000 after purchasing an additional 145 shares during the period. Institutional investors own 99.04% of the company's stock.

Insider Transactions at Glaukos

In related news, CFO Alex R. Thurman sold 10,000 shares of Glaukos stock in a transaction dated Thursday, July 16th. The shares were sold at an average price of $160.00, for a total transaction of $1,600,000.00. Following the completion of the transaction, the chief financial officer directly owned 43,906 shares of the company's stock, valued at $7,024,960. This trade represents a 18.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gilbert H. Kliman sold 5,000 shares of the business's stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $140.76, for a total transaction of $703,800.00. Following the sale, the director directly owned 35,528 shares in the company, valued at $5,000,921.28. The trade was a 12.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 40,525 shares of company stock valued at $6,116,806 in the last three months. 5.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Wells Fargo & Company upped their price target on Glaukos from $138.00 to $178.00 and gave the company an "overweight" rating in a research report on Thursday, July 30th. Truist Financial boosted their price objective on shares of Glaukos from $180.00 to $215.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. HC Wainwright upped their price objective on shares of Glaukos from $168.00 to $195.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. UBS Group started coverage on shares of Glaukos in a research report on Tuesday, July 28th. They issued a "neutral" rating and a $150.00 target price for the company. Finally, BTIG Research lifted their target price on shares of Glaukos from $164.00 to $193.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Twelve investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $177.33.

Glaukos Trading Down 0.0%

GKOS opened at $170.88 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $184.00. The stock has a market cap of $10.08 billion, a PE ratio of -52.58 and a beta of 0.78. The business has a 50 day moving average of $142.71 and a 200-day moving average of $126.82.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to analysts' expectations of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm's revenue for the quarter was up 49.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.24) earnings per share. Equities research analysts predict that Glaukos Corporation will post -0.35 earnings per share for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source